0001104659-26-034162
SEC filingProMIS Neurosciences Inc. reported financial results for the year ended December 31, 2025, with a net loss of $39.7 million, cash of $6.1 million, R&D expenses of $33.4 million, and G&A expenses of $6.8 million. The company completed enrollment of 144 patients in the PRECISE-AD Phase 1b trial for PMN310 and closed a $75.5 million private placement in February 2026, providing cash runway through 2027.